RT Journal Article
SR Electronic
T1 Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.21.21255888
DO 10.1101/2021.04.21.21255888
A1 Georgia C Richards
A1 Jeffrey K Aronson
A1 Brian MacKenna
A1 Ben Goldacre
A1 FD Richard Hobbs
A1 Carl Heneghan
YR 2021
UL http://medrxiv.org/content/early/2021/04/23/2021.04.21.21255888.abstract
AB Background Opioid prescribing trends have been well investigated in many countries. However, the patterns of opioids purchased over-the-counter (OTC) without a prescription are mostly unknown. Codeine is an opioid that is widely available OTC in many countries. We aimed to assess national sales and public expenditure of OTC codeine-containing products purchased in 31 countries between 2013 and 2019.Methods We conducted a retrospective observational study using electronic point-of-sale data from IQVIA. Countries included Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Latvia, Lithuania, Mexico, The Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, the UK, and the USA. We calculated the annual mean volume of sales per 1000 of the population and public expenditure (GBP, £ per 1000) between April 2013 and March 2019. We quantified changes over time and the types of products sold.Results 31.5 billion units of codeine, costing £2.55 billion, were sold OTC in 31 countries between April 2013 and March 2019. Total sales increased by 3% (3025 units/1000 in 2013 to 3111 in 2019) and public expenditure doubled (£196/1000 in 2013 to £301 in 2019). Sales were not equally distributed across the 31 countries. South Africa accounted for the largest mean volume of sales (31 units/person), followed by Ireland (24 units/person), France (16 units/person), Latvia (15 units/person), and the UK (11 units/person). The types of products (n=569) and formulations (n=12) varied.Conclusions In many parts of the world, a substantial number of people may be purchasing and consuming codeine from OTC products. Clinicians should ask patients about their use of OTC products. Public health measures are required to identify and prevent codeine misuse and abuse, increase awareness and education about the harms of codeine, and review medicines legislation to improve the collection of such data.Pre-registration https://doi.org/10.17605/OSF.IO/AY4MCCompeting Interest StatementGCR was financially supported by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR), the Naji Foundation, and the Rotary Foundation to study for a Doctor of Philosophy (2017-2020), but no longer has any financial COIs. GCR is an Associate Editor of BMJ Evidence Based Medicine. JKA has published articles and edited textbooks on adverse drug reactions and interactions and has often given medicolegal advice, including appearances as an expert witness in coroners' courts, often dealing with the adverse effects of opioids. BM works for NHS England as a pharmacist adviser. BG has received research funding from the Laura and John Arnold Foundation, the NIHR, the NIHR SPCR, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK (HDRUK), the Health Foundation, and the World Health Organisation (WHO); he also receives personal income from speaking and writing for lay audiences on the misuse of science. FDRH acknowledges part support from the NIHR School for Primary Care Research (SPCR), the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, and the NIHR Oxford OUH BRC. CH is an NIHR Senior Investigator and has received expenses and fees for his media work, received expenses from the WHO, FDA, and holds grant funding from the NIHR SPCR and the NIHR SPCR Evidence Synthesis Working Group [Project 380], the NIHR BRC Oxford and the WHO. On occasion, CH receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract with Oxford Health NHS Foundation Trust). CH is the Director of the CEBM. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Clinical Protocols https://doi.org/10.17605/OSF.IO/AY4MC Funding StatementThe Primary Care Research Trust of Birmingham and Midlands Research Practices Consortium provided the funds to purchase the sales data from IQVIA. The sponsor was not involved in the study design, collection, analysis or interpretation of data, writing of the manuscript, or decisions on submitting the manuscript for publication. The researchers had full access to all the data used in this study, which was independent from the funders. The authors take responsibility for the integrity of the data and the accuracy of the data analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not appliciableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy materials, protocol, and statistical code are openly available on our OSF repository [64] (https://osf.io/yt6bf/) and at GitHub [61] (https://github.com/georgiarichards/otc_codeine). We cannot openly share the data owing to contractual agreements with IQVIA, but the data can be accessed directly from IQVIA, which will require a fee. https://osf.io/yt6bf/ https://github.com/georgiarichards/otc_codeine